Our findings suggest that BRG1 may be a crucial mediator in peritoneal fibrosis and MCL targeting BRG1 may be a novel therapeutic strategy to treat PD-related peritoneal fibrosis. Here, SMARCA4 is linked to Peritoneal Fibrosis.